Pre-made Miptenalimab benchmark antibody ( Whole mAb, anti-LAG3 therapeutic antibody, Anti-CD223 Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-346
Pre-Made Miptenalimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Miptenalimab (formerly BI 754111) is a humanised IgG4 anti-lymphocyte-activation gene 3 (LAG3) monoclonal antibody and an immune checkpoint inhibitor, being developed by Boehringer Ingelheim for the treatment of solid tumours, head and neck cancer and non-small cell lung cancer.
Order information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
---|---|---|---|---|
GMP-Bios-ab-346-1mg | 1mg | 3090 | Inquiry | Inquiry |
Size: 1mg | 10mg | 100mg
Description
Products Name (INN Index) | Pre-Made Miptenalimab biosimilar, Whole mAb, Anti-LAG3 Antibody: Anti-CD223 therapeutic antibody |
INN Name | Miptenalimab |
Target | LAG3 |
Format | Whole mAb |
Derivation | |
Species Reactivity | Human |
CH1 Isotype | IgG4 |
VD LC | Kappa |
Highest_Clin_Trial (Jan '20) | Phase-II |
Est. Status | Active |
100% SI Structure | None |
99% SI Structure | None |
95-98% SI Structure | None |
Year Proposed | 2019 |
Year Recommended | 2020 |
Companies | Boehringer Ingelheim |
Conditions Approved | na |
Conditions Active | Solid tumours;Head and neck cancer;Non-small cell lung cancer |
Conditions Discontinued | na |
Development Tech | na |
- GENEMEDI
- Email: [email protected] [email protected]
- Telephone: +86-21-50478399 Fax: 86-21-50478399
- Privacy Policy
- TECHNICAL SUPPORT
- Product FAQs
- Technical manuals
- Publications
- Email: [email protected]
<